Form 4: Intra-Cellular Therapies EVP Suresh K. Durgam Reports Stock Transactions

EVP and Chief Medical Officer Suresh K. Durgam of Intra-Cellular Therapies, Inc. reports the vesting and conversion of restricted stock units into common stock.

Summary

• On March 6, 2024, Suresh K. Durgam, EVP and Chief Medical Officer of Intra-Cellular Therapies, Inc., reported transactions involving the company's stock.
• Durgam converted 13,132 restricted stock units into common stock.
• Following the reported transaction, Durgam directly owns 22,620 shares of common stock.
• The reported transaction also shows Durgam directly owns 26,266 restricted stock units.
• The restricted stock units were granted on March 6, 2023, and vest in three equal annual installments beginning on the first anniversary of the grant date.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of stock transactions, with no inherent positive or negative implications for the company's performance.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, which are common for executives at publicly traded companies. These filings provide transparency into the buying and selling activities of company insiders.

Stakeholder Impact

• Shareholders are informed about the stock transactions of a key executive, providing transparency into insider activity.

Key Dates